Version 5.7 – NDA / Full Technical Release (22 May 2026) This is the restricted full technical version of the OORU ZBO™ white paper. It contains additional proprietary technical details and Appendix 7 (Due Diligence – Strategic Partners & Potential Customers, including AstroForge assessment). Key Updates in v5.7:- Updated all feedstock terminology to “synthetically produced / engineered CO₂ clathrate hydrate”- Made the system fully launcher-agnostic- Added restricted Appendix 7 Access Note:This record is **RESTRICTED**. Access is available only to qualified parties who have executed a signed Non-Disclosure Agreement with Phill Hinds Technologies. Public open-access version (v5.7 Public) is available here: https://zenodo.org/records/20360849 For NDA access or further information, please contact: Phill.Hinds.tech@gmail.com
No takes yet. Share an insight, caveat, or question.
Phillip Ronald Hinds (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: